XAGE: מכפיל מחיר להכנסות Carmell Therapeutics Corporation

Stable supply chains for dermatological products ensure business resilience, as confirmed by the revenue multiple for Longevity Health Holdings (XAGE). The current value of 3.90 serves as an indicator of market valuation. Partnerships with plastic surgeons to promote plasma biomaterials are driving sales growth, while Longevity Health Holdings (XAGE) accumulates its primary capital through the sale of regenerative cosmetics for tissue rejuvenation.

The P/S multiple reflects the market value of one dollar of revenue by relating the total market capitalization of Longevity Health Holdings (XAGE) to its sales volume to assess investment attractiveness. By analyzing the price-to-sales dynamics, an investor can discern market expectations for business scaling within aesthetic medicine, where the high margins of patented products ensure sustainable revenue growth regardless of macroeconomic cycles.